Transdermal Peptide Delivery via Skin Ablation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Peptides with high molecular weights, such as triptorelin, desmopressin, and vasopressin, face challenges in transdermal administration due to low stability in solution and invasive injection methods, which result in low patient compliance and limited storage duration, along with difficulties in precise dosing and potential for infections.
Innovation Solution
A transdermal therapeutic system (TTS) comprising an active ingredient layer with a peptide and a hydrophilic carrier substance, such as polyvinylpyrrolidone, applied to ablatively treated skin to facilitate transdermal absorption, minimizing water content for stability and microbial susceptibility, and using a pressure-sensitive adhesive for adhesion without needles, enabling long-term application.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptides are administered by injection, then therapeutic efficacy is achieved, but patient compliance deteriorates and infection risk increases
Solution Approach 1:
The patent replaces the mechanical injection system (needles, syringes) with a transdermal delivery system that uses chemical permeation enhancement. The stratum corneum is temporarily disrupted using chemical agents (DMSO, ethanol) or physical methods (microneedles, iontophoresis) to allow peptide penetration without parenteral injection, thereby maintaining therapeutic efficacy while eliminating injection-related discomfort and infection risks.
2Ease of operation
If peptides are administered orally, then administration is simplified, but bioavailability deteriorates due to proteolytic degradation
Solution Approach 1:
The patent introduces the stratum corneum as an intermediary barrier that protects peptides from proteolytic degradation in the gastrointestinal tract. By delivering peptides through the skin (which lacks proteases in the same capacity as the GI tract), the system maintains peptide integrity while achieving simplified administration. The stratum corneum acts as a protective interface that enables oral-like simplicity with parenteral-level reliability.
3Reliability
If skin ablation is performed to increase permeability, then transdermal absorption of high-molecular-weight molecules is enabled, but skin integrity deteriorates and healing time increases
Solution Approach 1:
The patent applies partial skin ablation or temporary disruption rather than complete destruction. Methods such as microneedle arrays create controlled micro-channels, or chemical permeation enhancers temporarily alter stratum corneum structure. This partial action achieves sufficient peptide penetration while preserving overall skin integrity and minimizing healing time, avoiding the excessive damage caused by traditional full-thickness ablation techniques.
4Ease of operation
If peptides are formulated in aqueous solution for injection, then ease of administration is improved, but storage duration deteriorates due to low stability
Solution Approach 1:
The patent changes the physical and chemical parameters of peptide formulation by incorporating them into transdermal matrix systems (hydrogels, polymers, liposomes) or using lyophilized forms that are reconstituted at application. These parameter changes (encapsulation, drying, pH adjustment) enhance peptide stability during storage while maintaining ease of administration through simple patch application or microneedle insertion, eliminating the need for complex aqueous solution handling.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TTS provides stable, non-invasive, and cost-effective transdermal delivery of peptides, enhancing storage duration, reducing mechanical injury, and improving patient compliance by allowing precise dosing and minimizing microbial risks, while maintaining therapeutic efficacy through controlled peptide release.
Implementation Method 1
A transdermal therapeutic system (TTS) comprising an active ingredient layer with a peptide and a hydrophilic carrier substance, such as polyvinylpyrrolidone, applied to ablatively treated skin to facilitate transdermal absorption
Implementation Method 2
Another technique for making molecules with poor skin transit amenable to transdermal administration is to facilitate the passage of an active ingredient of this kind through the stratum corneum by partly destroying or removing this layer beforehand. These techniques, referred to as 'skin ablation'
Implementation Method 3
using a pressure-sensitive adhesive for adhesion without needles
Data Source
AI summary
The invention relates to a transdermal therapeutic system (TTS) which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system incorporates a back layer and an active substance-containing layer that includes at least one peptide and a carrier substance.